Historical Valuation
Nanobiotix SA (NBTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.39 is considered Undervalued compared with the five-year average of -4.69. The fair price of Nanobiotix SA (NBTX) is between 28.50 to 40.94 according to relative valuation methord. Compared to the current price of 20.54 USD , Nanobiotix SA is Undervalued By 27.93%.
Relative Value
Fair Zone
28.50-40.94
Current Price：20.54
27.93%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Nanobiotix SA (NBTX) has a current Price-to-Book (P/B) ratio of -13.21. Compared to its 3-year average P/B ratio of -32.16 , the current P/B ratio is approximately -58.93% higher. Relative to its 5-year average P/B ratio of -8.31, the current P/B ratio is about 58.95% higher. Nanobiotix SA (NBTX) has a Forward Free Cash Flow (FCF) yield of approximately -3.45%. Compared to its 3-year average FCF yield of -9.61%, the current FCF yield is approximately -64.08% lower. Relative to its 5-year average FCF yield of -11.53% , the current FCF yield is about -70.05% lower.
P/B
Median3y
-32.16
Median5y
-8.31
FCF Yield
Median3y
-9.61
Median5y
-11.53
Competitors Valuation Multiple
AI Analysis for NBTX
The average P/S ratio for NBTX competitors is 65.27, providing a benchmark for relative valuation. Nanobiotix SA Corp (NBTX.O) exhibits a P/S ratio of 14.39, which is -77.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for NBTX
1Y
3Y
5Y
Market capitalization of NBTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NBTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NBTX currently overvalued or undervalued?
Nanobiotix SA (NBTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.39 is considered Undervalued compared with the five-year average of -4.69. The fair price of Nanobiotix SA (NBTX) is between 28.50 to 40.94 according to relative valuation methord. Compared to the current price of 20.54 USD , Nanobiotix SA is Undervalued By 27.93% .
What is Nanobiotix SA (NBTX) fair value?
NBTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nanobiotix SA (NBTX) is between 28.50 to 40.94 according to relative valuation methord.
How does NBTX's valuation metrics compare to the industry average?
The average P/S ratio for NBTX's competitors is 65.27, providing a benchmark for relative valuation. Nanobiotix SA Corp (NBTX) exhibits a P/S ratio of 14.39, which is -77.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Nanobiotix SA (NBTX) as of Jan 10 2026?
As of Jan 10 2026, Nanobiotix SA (NBTX) has a P/B ratio of -13.21. This indicates that the market values NBTX at -13.21 times its book value.
What is the current FCF Yield for Nanobiotix SA (NBTX) as of Jan 10 2026?
As of Jan 10 2026, Nanobiotix SA (NBTX) has a FCF Yield of -3.45%. This means that for every dollar of Nanobiotix SA’s market capitalization, the company generates -3.45 cents in free cash flow.
What is the current Forward P/E ratio for Nanobiotix SA (NBTX) as of Jan 10 2026?
As of Jan 10 2026, Nanobiotix SA (NBTX) has a Forward P/E ratio of 163.39. This means the market is willing to pay $163.39 for every dollar of Nanobiotix SA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Nanobiotix SA (NBTX) as of Jan 10 2026?
As of Jan 10 2026, Nanobiotix SA (NBTX) has a Forward P/S ratio of 14.39. This means the market is valuing NBTX at $14.39 for every dollar of expected revenue over the next 12 months.